DE3587759T2 - Erhöhte Hefetranskription unter Verwendung einer Hybridkonstruktion der Promotorregion. - Google Patents
Erhöhte Hefetranskription unter Verwendung einer Hybridkonstruktion der Promotorregion.Info
- Publication number
- DE3587759T2 DE3587759T2 DE3587759T DE3587759T DE3587759T2 DE 3587759 T2 DE3587759 T2 DE 3587759T2 DE 3587759 T DE3587759 T DE 3587759T DE 3587759 T DE3587759 T DE 3587759T DE 3587759 T2 DE3587759 T2 DE 3587759T2
- Authority
- DE
- Germany
- Prior art keywords
- yeast
- promoter region
- pcl
- deposited
- sub
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8125—Alpha-1-antitrypsin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60954084A | 1984-05-11 | 1984-05-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
DE3587759D1 DE3587759D1 (de) | 1994-04-07 |
DE3587759T2 true DE3587759T2 (de) | 1994-07-07 |
Family
ID=24441222
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE3587759T Expired - Lifetime DE3587759T2 (de) | 1984-05-11 | 1985-05-03 | Erhöhte Hefetranskription unter Verwendung einer Hybridkonstruktion der Promotorregion. |
Country Status (4)
Country | Link |
---|---|
EP (2) | EP0164556B1 (de) |
AT (1) | ATE102250T1 (de) |
CA (1) | CA1281671C (de) |
DE (1) | DE3587759T2 (de) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5342921A (en) * | 1985-03-28 | 1994-08-30 | Chiron Corporation | Superoxide dismutase fusion polypeptides for expression of mammalian proteins |
US5523215A (en) * | 1985-03-28 | 1996-06-04 | Chiron Corporation | Enhanced purification and expression of insoluble recombinant proteins |
EP0225887B1 (de) * | 1985-04-08 | 1994-06-08 | Amgen Inc. | Verfahren und hybridpromotor zur steuerung der exogenen gentranskription |
GB8521496D0 (en) * | 1985-08-29 | 1985-10-02 | Ciba Geigy Ag | Repressible yeast promoters |
ES2028779T3 (es) * | 1985-10-03 | 1992-07-16 | Green Cross Corporation | Promotor de levadura y procedimiento para preparar proteina heterologa. |
EP0237913A1 (de) * | 1986-03-21 | 1987-09-23 | Miles Inc. | Transkriptions-Effektor-Sequenzen |
JPS62236496A (ja) * | 1986-04-07 | 1987-10-16 | Green Cross Corp:The | HBsAgの製造方法 |
CA1310602C (en) * | 1986-06-03 | 1992-11-24 | Hajime Horii | Yeast promoter and process for preparing heterologous protein |
GB8620926D0 (en) * | 1986-08-29 | 1986-10-08 | Delta Biotechnology Ltd | Yeast promoter |
EP0268772B1 (de) * | 1986-09-19 | 1995-04-26 | ZymoGenetics, Inc. | Expression des biologisch aktiven Faktors XIII |
US5013652A (en) * | 1986-10-14 | 1991-05-07 | Genex Corporation | Composite yeast vectors |
CA1340772C (en) | 1987-12-30 | 1999-09-28 | Patricia Tekamp-Olson | Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences |
NO177065C (no) * | 1988-09-26 | 1995-07-12 | Labofina Sa | Framgangsmåte for framstilling av enzymatisk aktivt humant lysozym |
JPH03155791A (ja) * | 1989-11-14 | 1991-07-03 | Green Cross Corp:The | 雑種プロモーター |
FR2656531B1 (fr) * | 1989-12-29 | 1992-04-24 | Sanofi Sa | Promoteur artificiel pour l'expression de proteines dans le levure. |
US6194140B1 (en) * | 1990-04-04 | 2001-02-27 | Chiron Corporation | HCV NS3 protein fragments having helicase activity and improved solubility |
JPH04108389A (ja) * | 1990-08-30 | 1992-04-09 | Tonen Corp | 酵母において機能する大腸菌由来上流制御配列 |
WO1992009698A1 (en) | 1990-11-26 | 1992-06-11 | Genetics Institute, Inc. | Expression of pace in host cells and methods of use thereof |
US5407822A (en) * | 1991-10-02 | 1995-04-18 | Sanofi | Artificial promoter for the expression of proteins in yeast |
LT3988B (en) | 1992-02-17 | 1996-06-25 | Fermentas Biotech Inst | Recombinant plasmides pfs19, pfps2-48 and pjlfds1 codingsynthesis of human hepatite b of surfice virus antigenes, methods fof producing thereof |
RU2115730C1 (ru) * | 1992-03-03 | 1998-07-20 | Акционерное общество "Биофа" | Рекомбинантная плазмида pfs 19, определяющая синтез поверхностного антигена s вируса гепатита b человека |
DE69433160T2 (de) | 1993-05-12 | 2004-07-08 | Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville | Konserviertes Motiv der Hepatitis C Virus E2/NS1 Region |
US5629167A (en) | 1994-04-19 | 1997-05-13 | Biocine S.P.A. | Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay |
ES2229288T3 (es) | 1995-12-22 | 2005-04-16 | Dsm Ip Assets B.V. | Metodos mejorados para transformar cepas de phaffia, cepas de phaffia transformadas asi obtenidas y dna recombinante en dichos metodos. |
GB2318732A (en) | 1996-11-01 | 1998-05-06 | Johnson & Johnson Medical | Wound healing compositions containing alpha-1-antitrypsin |
US6265186B1 (en) | 1997-04-11 | 2001-07-24 | Dsm N.V. | Yeast cells comprising at least two copies of a desired gene integrated into the chromosomal genome at more than one non-ribosomal RNA encoding domain, particularly with Kluyveromyces |
EP1029052B1 (de) | 1997-11-06 | 2010-08-04 | Novartis Vaccines and Diagnostics S.r.l. | Neisseriale antigene |
DE69941567D1 (de) | 1998-01-14 | 2009-12-03 | Novartis Vaccines & Diagnostic | Antigene aus neisseria meningitidis |
US6087128A (en) | 1998-02-12 | 2000-07-11 | Ndsu Research Foundation | DNA encoding an avian E. coli iss |
GB9808932D0 (en) | 1998-04-27 | 1998-06-24 | Chiron Spa | Polyepitope carrier protein |
ES2294629T3 (es) | 1998-05-01 | 2008-04-01 | Novartis Vaccines And Diagnostics, Inc. | Antigenos de neisseria y composiciones. |
ES2397918T3 (es) | 1999-04-30 | 2013-03-12 | Novartis Vaccines And Diagnostics S.R.L. | Antígenos Neisseriales conservados |
GB9911683D0 (en) | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
US6297013B1 (en) | 1999-06-24 | 2001-10-02 | Dnab Diagnostics Inc. | Compositions and methods for determining the activity of DNA-binding proteins and of initiation of transcription |
GB9916529D0 (en) | 1999-07-14 | 1999-09-15 | Chiron Spa | Antigenic peptides |
ES2564463T3 (es) | 1999-10-29 | 2016-03-22 | Glaxosmithkline Biologicals S.A. | Péptidos antigénicos de Neisseriales |
US6709863B2 (en) | 1999-12-08 | 2004-03-23 | Iowa State University Research Foundation | Nucleic acid molecules encoding multiple start codons and histidine tags |
PT2289545T (pt) | 2000-01-17 | 2016-09-06 | Glaxosmithkline Biologicals Sa | Vacina de omv suplementada contra meningococos |
EP2284182A1 (de) | 2000-10-27 | 2011-02-16 | Novartis Vaccines and Diagnostics S.r.l. | Nukleinsäuren und Proteine von Streptokokkengruppen A und B |
GB0107658D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Streptococcus pneumoniae |
GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
EP2335723A1 (de) | 2001-12-12 | 2011-06-22 | Novartis Vaccines and Diagnostics S.r.l. | Immunisierung gegen Chlamydia trachomatis |
EP1572720A4 (de) | 2002-05-24 | 2008-12-24 | Nps Allelix Corp | Verfahren zur enzymatischen herstellung von glp-2-(1-33)- und glp-2-(1-34)-peptiden |
AU2003288660A1 (en) | 2002-11-15 | 2004-06-15 | Chiron Srl | Unexpected surface proteins in neisseria meningitidis |
GB0308198D0 (en) | 2003-04-09 | 2003-05-14 | Chiron Srl | ADP-ribosylating bacterial toxin |
ES2380765T3 (es) | 2003-11-21 | 2012-05-18 | Nps Pharmaceuticals, Inc. | Producción del péptido 2 de tipo glucagón y análogos |
BRPI0507169A (pt) | 2004-02-02 | 2007-06-26 | Ambrx Inc | polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos |
CA2762011C (en) | 2004-04-09 | 2019-05-07 | Monsanto Technology Llc | Compositions and methods for control of insect infestations in plants |
JP2008503217A (ja) | 2004-06-18 | 2008-02-07 | アンブレツクス・インコーポレイテツド | 新規抗原結合ポリペプチド及びそれらの使用 |
US7385028B2 (en) | 2004-12-22 | 2008-06-10 | Ambrx, Inc | Derivatization of non-natural amino acids and polypeptides |
KR20070090023A (ko) | 2004-12-22 | 2007-09-04 | 암브룩스, 인코포레이티드 | 변형 인간 성장 호르몬 |
EP2339014B1 (de) | 2005-11-16 | 2015-05-27 | Ambrx, Inc. | Verfahren und Zusammensetzungen mit nichtnatürlichen Aminosäuren |
CA2631491C (en) | 2005-12-14 | 2015-02-24 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
PL2054431T3 (pl) | 2006-06-09 | 2012-07-31 | Novartis Ag | Konformery adhezyn bakteryjnych |
EP2615108B1 (de) | 2006-09-08 | 2016-10-26 | Ambrx, Inc. | Modifiziertes humanes Plasmapolypeptid oder Fc-Gerüste und deren Verwendungen |
ES2385114T3 (es) | 2007-03-30 | 2012-07-18 | Ambrx, Inc. | Polipéptidos de FGF-21 modificados y sus usos |
NZ603812A (en) | 2007-11-20 | 2014-06-27 | Ambrx Inc | Modified insulin polypeptides and their uses |
CN101939443B (zh) | 2008-02-08 | 2014-01-29 | Ambrx公司 | 经修饰瘦素多肽和其用途 |
UA103774C2 (uk) | 2008-07-23 | 2013-11-25 | Амбркс, Інк. | Модифіковані поліпептиди бичачого гранулоцитарного колонієстимулювального фактора (g-csf) та їх застосування |
WO2010036964A2 (en) | 2008-09-26 | 2010-04-01 | Ambrx Inc. | Modified animal erythropoietin polypeptides and their uses |
DK2337846T3 (en) | 2008-09-26 | 2018-03-12 | Ambrx Inc | NON-NATURAL AMINO ACID REPLICATION DEPENDENT MICROORGANISMS AND VACCINES |
NZ600361A (en) | 2009-12-21 | 2014-06-27 | Ambrx Inc | Modified bovine somatotropin polypeptides and their uses |
CN102666578A (zh) | 2009-12-21 | 2012-09-12 | Ambrx公司 | 经过修饰的猪促生长素多肽和其用途 |
US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
KR101963460B1 (ko) | 2010-08-17 | 2019-03-28 | 암브룩스, 인코포레이티드 | 변형된 릴랙신 폴리펩타이드 및 그것의 용도 |
AR083006A1 (es) | 2010-09-23 | 2013-01-23 | Lilly Co Eli | Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas |
ES2874331T3 (es) | 2014-10-24 | 2021-11-04 | Bristol Myers Squibb Co | Polipéptidos de FGF-21 modificados y usos de los mismos |
MY193457A (en) | 2017-02-08 | 2022-10-14 | Bristol Myers Squibb Co | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GR76274B (de) * | 1981-08-04 | 1984-08-04 | Univ California | |
NZ201705A (en) * | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
AU577259B2 (en) * | 1982-08-13 | 1988-09-22 | Zymogenetics Inc. | Glycolytic promters for regulated protein expression protease inhibitor |
GB8314961D0 (en) * | 1983-05-31 | 1983-07-06 | Kingsman A J | Dna sequence |
DE3486493T2 (de) * | 1983-10-03 | 2003-05-22 | Chiron Corp | Klonieren von Superoxiddismutase und Expression in Mikroorganismen |
EP0164719B1 (de) * | 1984-06-14 | 1992-05-06 | Chiron Corporation | Protease-Inhibitoren des Alpha-1-Antitrypsin Typs mit modifizierter aktiever Stelle und deren Herstellung |
CA1341423C (en) * | 1984-10-31 | 2003-03-04 | Paul A. Luciw | Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome |
ATE63757T1 (de) * | 1985-03-28 | 1991-06-15 | Chiron Corp | Expression durch verwendung von fusionsgenen fuer proteinproduktion. |
-
1985
- 1985-05-03 EP EP85105405A patent/EP0164556B1/de not_active Expired - Lifetime
- 1985-05-03 AT AT85105405T patent/ATE102250T1/de not_active IP Right Cessation
- 1985-05-03 DE DE3587759T patent/DE3587759T2/de not_active Expired - Lifetime
- 1985-05-03 EP EP19910121606 patent/EP0480480A3/en not_active Withdrawn
- 1985-05-13 CA CA000481401A patent/CA1281671C/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
EP0164556B1 (de) | 1994-03-02 |
CA1281671C (en) | 1991-03-19 |
ATE102250T1 (de) | 1994-03-15 |
DE3587759D1 (de) | 1994-04-07 |
EP0164556A2 (de) | 1985-12-18 |
EP0480480A2 (de) | 1992-04-15 |
EP0480480A3 (en) | 1992-06-10 |
EP0164556A3 (en) | 1987-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3587759D1 (de) | Erhöhte Hefetranskription unter Verwendung einer Hybridkonstruktion der Promotorregion. | |
WO1998027114A3 (en) | Mammalian cell surface antigens; related reagents | |
EP0260148A3 (de) | Rekombinantes Expressionsverfahren, Vektor und tranformierte Zellen | |
EP0185444A3 (en) | Cloning and expression of htlv-iii dna | |
EP1064403A4 (de) | Antisense modulation von pecam-1 | |
ES8603957A1 (es) | Procedimiento para obtener una proteina heterologa para levadura | |
DE3851309T2 (de) | Transfizierte Zellstämme, die den menschlichen Rhinovirus-Hauptrezeptor exprimieren. | |
EP1114864A3 (de) | Oberflächenantigene aus Säugern mit Strukturmotifen die charakteristisch für Mitglieder der TNF Liganden Familie sind | |
EP0248637A3 (de) | Induktion von Galaktose regulierter Genexpression in Hefe | |
DE69128619T2 (de) | Mit den für xylosereduktase und xylitoldehydrogenase kodierenden dns-sequenzen rekombinierte hefen | |
KR960705929A (ko) | 신규한 Fas 단백질 및 그것의 사용방법(NOVEL FAS PROTEIN AND METHODS OF USE THEREOF) | |
DE3585578D1 (de) | Hepatitisoberflaechenantigenpartikelvakzin. | |
EP0228036A3 (de) | Verfahren zur Herstellung von spezifischen Polypeptiden in virusinfizierten Insektzellen und daraus isolierte Polypeptide | |
AU5961596A (en) | Method for expression and isolation of biologically active m olecules in urine | |
EP0132309A3 (de) | Regulierbares eukaryotisches Promotorelement | |
DE3773512D1 (de) | Vektor und verfahren zur erreichung einer hohen expression in zellen. | |
FI970428A0 (fi) | Soluja, joissa on CD4-houkutusreseptoreita ja vastaavia molekyylejä ja menetelmiä | |
WO2000015772A3 (en) | Recombinant protein production in urine | |
ES2075068T3 (es) | Procedimiento de preparacion de una proteina mediante levaduras que utiliza un sistema inducible, vectores y cepas transformadas correspondientes. | |
KR880701285A (ko) | Aids 비루스의 f단백질을 함유하는 백신 | |
AU1695595A (en) | Mammalian thymokine genes | |
KR890004727A (ko) | Hiv-2 비루스 단백질의 발현을 위한 벡터, aids의 원인체중 하나, 이 비루스에 의해 감염되거나 형질 전환된 세포 배양물, 얻어진 단백질, 얻어진 백신 및 항체 | |
KR880004092A (ko) | 두창비루스의 a-형 봉입체용 유전자 | |
EP0385394A3 (de) | Polyhedringen und gentechnologische Anwendung | |
BR8605221A (pt) | Metodo de expressao de genes em levedura,fragmento de dna e plasmidio |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |